Radiotherapy Enhances the Oncolytic Efficacy of the Novel Oncolytic Herpesvirus VG161 and Amplifies Its Antitumor Immunity in Breast Cancer
Advanced Science · 2026
DOI: 10.1002/advs.202523356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Lijuan Lyu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Oncolytic Virotherapy, Oncolytic Viruses, Herpesvirus 1, Human. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
VG161 is an oncolytic HSV‐1 with an ICP34.5 deletion and armed with multiple immunomodulatory factors. The absence of ICP34.5 restricts viral replication in neurons while conferring tumor specificity. However, this modification attenuates viral replication in tumor cells compared to wild‐type HSV‐1. Radiotherapy (RT) has been reported to promote viral replication and exert an immune‐priming effect. Based on this, we hypothesize that RT could potentiate both the VG161 replication and its antitumor efficacy in breast cancer (BC). Our findings suggest that the optimal regimen for combining VG161 with RT involves administering 5 Gy irradiation 6 h after VG161 infection, which ensures that RT maximally promotes VG161 replication in BC. This enhancement in VG161 replication is mediated by the upregulation of GADD34 and HVEM induced by RT. Moreover, RT augments the expression of immunostimulatory transgenes carried by VG161 and immunogenic cell death of BC cells. In vivo, VG161 combined with RT demonstrates superior antitumor efficacy compared with either monotherapy in BC. Mechanistic investigations reveal that this combination therapy increases the abundances of tumor‐infiltrating lymphocytes and elicits potent systemic antitumor immunity that inhibits local tumors and regresses abscopal metastases. The observed synergistic effect of VG161 and RT encourages further clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Surgery, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
- Department of General Surgery, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, China.
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Zhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, China.
- Shanghai Virogin Biotech Co., Ltd., Shanghai, China.
- Department of Hepatobiliary and Pancreatic Surgery, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
ORCID-Profile: Zhijun Dai
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lyu, L., Yi, M., Chen, J., Zhao, Z., Liao, R., Wang, Y., Hu, S., Ding, J., Zhao, R., Jia, W., Shen, Y., Wei, Y., Wu, K., & Dai, Z. (2026). Radiotherapy Enhances the Oncolytic Efficacy of the Novel Oncolytic Herpesvirus VG161 and Amplifies Its Antitumor Immunity in Breast Cancer. Advanced Science. https://doi.org/10.1002/advs.202523356
Vancouver
Lyu L, Yi M, Chen J, Zhao Z, Liao R, Wang Y, et al. Radiotherapy Enhances the Oncolytic Efficacy of the Novel Oncolytic Herpesvirus VG161 and Amplifies Its Antitumor Immunity in Breast Cancer. Advanced Science. 2026. doi:10.1002/advs.202523356
BibTeX
@article{Lyu2026,
author = {Lyu, Lijuan and Yi, Ming and Chen, Ji and Zhao, Zeda and Liao, Ruocen and Wang, Yingnan and Hu, Shengtao and Ding, Jun and Zhao, Ronghua and Jia, William and Shen, Yinan and Wei, Yongchang and Wu, Kongming and Dai, Zhijun},
title = {Radiotherapy Enhances the Oncolytic Efficacy of the Novel Oncolytic Herpesvirus VG161 and Amplifies Its Antitumor Immunity in Breast Cancer},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202523356}
}
EUVIMED